TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma
The primary objective of this study is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety profile of CHIR-258 when administered to subjects with refractory or relapsed multiple myeloma (MM).
Multiple Myeloma
DRUG: TKI258
Maximum tolerated dose|Dose limiting toxicity|Safety profile
Evaluation of pharmacokinetics and pharmacodynamics
The primary objective of this study is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety profile of CHIR-258 when administered to subjects with refractory or relapsed multiple myeloma (MM).